Geron Corp.. (GERN) NASDAQ

$3.45 (0.32) (-8.49%)

Market Cap: $1.99B

As of 04/15/24 03:59 PM EDT. Market closed.

(GERN)

Geron Corp.. (GERN)
NASDAQ

$3.45
(0.32) (-8.49%)

Market Cap: $1.99B

As of 04/15/24 03:59 PM EDT. Market closed.

Add to Portfolio

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on ... read more

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
John Scarlett
Full Time Employees
291
CEO Compensation (Base)
$667,000
CEO Compensation (Total)
$2.77M
URL
Address
919 East Hillsdale Boulevard, Suite 250, California, Foster City, 94404.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
John Scarlett
Full Time Employees
291
CEO Compensation (Base)
$667,000
CEO Compensation (Total)
$2.77M
Address
919 East Hillsdale Boulevard, Suite 250, California, Foster City, 94404.
PRICE CHART FOR GERON CORP.
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$3.67
Previous Close
$3.77
Days Range
$3.58 - $4.05
52 week range
$1.64 - $4.05
Volume
11,912,794
Avg. Volume (30 days)
12,520,819
Market Cap
$1.99B
Dividend Yield
-
P/E
(10.81)
Shares Outstanding
546,873,894
Open
$3.67
Previous Close
$3.77
Days Range
$3.58 - $4.05
52 week range
$1.64 - $4.05
Volume
11,912,794
Avg. Volume (30 days)
12,520,819
Market Cap
$1.99B
Dividend Yield
-
P/E
(10.81)
Shares Outstanding
546,873,894
FINANCIAL STATEMENTS FOR GERON CORP.
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR GERON CORP.
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
O'Farrell Elizabeth G.DirectorAug 24, 2023 Buy$2.286,57915,00026,220Aug 24, 2023, 08:52 PM
O'Farrell Elizabeth G.DirectorAug 24, 2023 Buy$2.286,60715,0647,407Aug 24, 2023, 08:52 PM
Kapur AnilEVP, Corp Strategy & CCOJun 30, 2023 Option Exercise$2.047,56715,43760,783Jun 30, 2023, 09:18 PM
LAWLIS V BRYANDirectorMay 11, 2023 Option Exercise$1.1035,00038,50035,000May 11, 2023, 09:01 PM
LAWLIS V BRYANDirectorMay 11, 2023 Sale$3.0035,000105,0000May 11, 2023, 09:01 PM
Molineaux SusanDirectorMay 01, 2023 Option Exercise$1.1035,00038,50035,000May 01, 2023, 09:20 PM
Molineaux SusanDirectorMay 01, 2023 Sale$2.4835,00086,8000May 01, 2023, 09:20 PM
GRETHLEIN ANDREW JEVP, Chief Operating OfficerFeb 09, 2023 Option Exercise$1.51150,000226,500384,719Feb 10, 2023, 09:49 PM
GRETHLEIN ANDREW JEVP, Chief Operating OfficerFeb 09, 2023 Sale$3.03384,7191,165,699234,719Feb 10, 2023, 09:49 PM
Bloom Olivia KyusukEVP, Chief Financial OfficerFeb 08, 2023 Option Exercise$1.51400,000604,000474,588Feb 10, 2023, 09:48 PM
Bloom Olivia KyusukEVP, Chief Financial OfficerFeb 08, 2023 Sale$3.08400,0001,232,00074,588Feb 10, 2023, 09:48 PM
SCARLETT JOHN AChairman, President and CEOFeb 08, 2023 Option Exercise$1.50446,666669,999446,666Feb 10, 2023, 09:47 PM
SCARLETT JOHN AChairman, President and CEOFeb 10, 2023 Option Exercise$1.50446,668670,002446,668Feb 10, 2023, 09:47 PM
SCARLETT JOHN AChairman, President and CEOFeb 09, 2023 Option Exercise$1.50446,666669,999446,666Feb 10, 2023, 09:47 PM
SCARLETT JOHN AChairman, President and CEOFeb 08, 2023 Sale$3.08446,6661,375,7310Feb 10, 2023, 09:47 PM
SCARLETT JOHN AChairman, President and CEOFeb 10, 2023 Sale$3.00446,6681,340,0040Feb 10, 2023, 09:47 PM
SCARLETT JOHN AChairman, President and CEOFeb 09, 2023 Sale$3.03446,6661,353,3980Feb 10, 2023, 09:47 PM
EASTHAM KARINDirectorJan 13, 2023 Option Exercise$1.1035,00038,500109,047Jan 17, 2023, 07:01 PM
Kapur AnilEVP, Corp Strategy & CCODec 30, 2022 Option Exercise$1.116,0216,68353,216Jan 03, 2023, 08:55 PM
GRETHLEIN ANDREW JEVP, Chief Operating OfficerSep 12, 2022 Option Exercise$1.70234,719399,022234,719Sep 14, 2022, 05:47 PM
Kapur AnilEVP, Corp Strategy & CCOJun 30, 2022 Option Exercise$1.1113,06214,49947,195Jul 01, 2022, 09:25 PM
EASTHAM KARINDirectorApr 20, 2022 Option Exercise$1.4135,00049,35074,047Apr 21, 2022, 08:09 PM
O'Farrell Elizabeth G.DirectorAug 21, 2020 Buy$1.7317,44130,17319,641Aug 24, 2020, 08:57 PM
O'Farrell Elizabeth G.DirectorJan 10, 2020 Buy$1.342,2002,9482,200Jan 13, 2020, 09:10 PM
O'Farrell Elizabeth G.DirectorJan 10, 2020 Buy$1.358001,080800Jan 13, 2020, 09:10 PM
BEHRS MELISSA KELLYEVP, Chief Business OfficerApr 09, 2019 Sale$2.00120,635241,2700Apr 10, 2019, 07:45 PM
Spiegel Robert J.DirectorSep 13, 2018 Option Exercise$2.95175,000516,550110,576Sep 13, 2018, 09:28 PM
Spiegel Robert J.DirectorSep 13, 2018 Sale$6.85175,0001,198,75065,576Sep 13, 2018, 09:28 PM
ROSENFIELD STEPHENEVP, Genl Counsel & SecretaryAug 24, 2018 Option Exercise$1.891,362,2502,572,745425,000Aug 24, 2018, 09:32 PM
ROSENFIELD STEPHENEVP, Genl Counsel & SecretaryAug 24, 2018 Sale$4.511,362,2506,143,7480Aug 24, 2018, 09:32 PM
Bloom Olivia KyusukEVP, Chief Financial OfficerMay 29, 2015 Sale$3.842,3809,13974,588Jun 01, 2015, 09:12 PM
BEHRS MELISSA KELLYEVP BD and Port&Alliance MgmtMay 29, 2015 Sale$3.842,3809,139120,635Jun 01, 2015, 09:12 PM
Hofstaetter ThomasDirectorMar 18, 2015 Option Exercise$1.2570,00087,85096,564Mar 19, 2015, 07:27 PM
Hofstaetter ThomasDirectorMar 18, 2015 Sale$4.1070,000287,00026,564Mar 19, 2015, 07:27 PM
Bloom Olivia KyusukEVP, Chief Financial OfficerMay 29, 2014 Sale$2.103,3797,09681,968May 30, 2014, 08:56 PM
BEHRS MELISSA KELLYEVP Portfolio & Alliance MgmtMay 29, 2014 Sale$2.104,82610,135143,015May 30, 2014, 08:50 PM
BRADBURY DANIELDirectorMay 09, 2014 Buy$1.75142,776249,858142,776May 12, 2014, 07:45 PM
Bloom Olivia KyusukEVP, Chief Financial OfficerApr 01, 2014 Sale$2.137,43515,83785,347Apr 02, 2014, 06:11 PM
BEHRS MELISSA KELLYEVP Portfolio & Alliance MgmtApr 01, 2014 Sale$2.1312,31026,220147,841Apr 02, 2014, 06:07 PM
SCARLETT JOHN APresident and CEOApr 01, 2013 Buy$1.0350,00051,500125,000Apr 01, 2013, 09:46 PM
BEHRS MELISSA KELLYSVP Alliance and Prog MgmtJan 17, 2013 Sale$1.6528,29246,5690Jan 22, 2013, 08:12 PM
Kelsey Stephen MichaelEVP, R&D Head, CMOMay 30, 2012 Sale$1.379,30012,741473,122Jun 01, 2012, 08:15 PM
EARP DAVIDSVP, Corp TransactionsMay 30, 2012 Sale$1.3727,15537,202467,406Jun 01, 2012, 08:15 PM
Bloom Olivia KyusukVP, Chief Acctg OfficerMay 30, 2012 Sale$1.3711,02915,110147,782Jun 01, 2012, 08:14 PM
BEHRS MELISSA KELLYSVP Strategic Portfolio MgmtMay 30, 2012 Sale$1.3718,91025,907405,151Jun 01, 2012, 08:14 PM
SCARLETT JOHN APresident and CEOJan 24, 2012 Buy$1.7275,000129,00075,000Feb 08, 2012, 08:29 PM
SCARLETT JOHN APresident and CEOJan 24, 2012 Option Exercise$1.7275,000129,00075,000Jan 25, 2012, 05:42 PM
KILEY THOMASDirectorNov 22, 2011 Buy$1.5664,275100,269314,059Nov 23, 2011, 06:51 PM
KILEY THOMASDirectorOct 05, 2011 Buy$2.0350,000101,50096,653Oct 06, 2011, 08:35 PM
Spink Katharine E.SVP Alliance Mgmt & OperationsJun 14, 2011 Sale$4.2822,59196,689328,561Jun 16, 2011, 09:06 PM
LEBKOWSKI JANESVP, Chief Scientific OfficerJun 14, 2011 Sale$4.2825,262108,121568,154Jun 16, 2011, 09:05 PM
Kelsey Stephen MichaelEVP, R&D Head, CMOJun 14, 2011 Sale$4.284,85820,792476,773Jun 16, 2011, 09:04 PM
BEHRS MELISSA KELLYSVP Strategic Portfolio MgmtJun 14, 2011 Sale$4.2825,262108,121424,061Jun 16, 2011, 09:03 PM
GREENWOOD DAVIDPresident, Interim CEO, CFOJun 14, 2011 Sale$4.2834,005145,541754,031Jun 16, 2011, 09:02 PM
EARP DAVIDChief Legal CounselJun 14, 2011 Sale$4.2825,262108,121494,561Jun 16, 2011, 08:58 PM
Bloom Olivia KyusukVP, Chief Acctg OfficerJun 14, 2011 Sale$4.286,99729,947158,811Jun 16, 2011, 08:57 PM
Bloom Olivia KyusukVP, Chief Acctg OfficerMay 24, 2011 Sale$4.471,2005,364165,808May 24, 2011, 09:41 PM
Spink Katharine E.SVP Prgm Mgmt, Cell TherapiesMay 24, 2011 Sale$4.474191,873351,152May 24, 2011, 09:40 PM
BEHRS MELISSA KELLYSVP Strategic Portfolio MgmtMay 24, 2011 Sale$4.472,97513,298449,323May 24, 2011, 09:40 PM
EARP DAVIDSVP Bus Dev, Chief Patnt CounsMay 24, 2011 Sale$4.472,97513,298519,823May 24, 2011, 09:39 PM
LEBKOWSKI JANESVP, Chief Scientific OfficerMay 24, 2011 Sale$4.472,97513,298593,416May 24, 2011, 09:39 PM
GREENWOOD DAVIDPresident, Interim CEO, CFOMay 24, 2011 Sale$4.474,46219,945788,036May 24, 2011, 09:38 PM
Kelsey Stephen MichaelEVP, CMO, OncologyMay 05, 2011 Sale$4.8314,16368,407364,131May 06, 2011, 08:09 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
O'Farrell Elizabeth G.Director08/24/202315,000
O'Farrell Elizabeth G.Director08/24/202315,064
Kapur AnilEVP, Corp Strategy & CCO06/30/202315,437
LAWLIS V BRYANDirector05/11/202338,500
LAWLIS V BRYANDirector05/11/2023105,000
Molineaux SusanDirector05/01/202338,500
Molineaux SusanDirector05/01/202386,800
GRETHLEIN ANDREW JEVP, Chief Operating Officer02/09/2023226,500
GRETHLEIN ANDREW JEVP, Chief Operating Officer02/09/20231,165,699
Bloom Olivia KyusukEVP, Chief Financial Officer02/08/2023604,000
Bloom Olivia KyusukEVP, Chief Financial Officer02/08/20231,232,000
SCARLETT JOHN AChairman, President and CEO02/08/2023669,999
SCARLETT JOHN AChairman, President and CEO02/10/2023670,002
SCARLETT JOHN AChairman, President and CEO02/09/2023669,999
SCARLETT JOHN AChairman, President and CEO02/08/20231,375,731
SCARLETT JOHN AChairman, President and CEO02/10/20231,340,004
SCARLETT JOHN AChairman, President and CEO02/09/20231,353,398
EASTHAM KARINDirector01/13/202338,500
Kapur AnilEVP, Corp Strategy & CCO12/30/20226,683
GRETHLEIN ANDREW JEVP, Chief Operating Officer09/12/2022399,022
Kapur AnilEVP, Corp Strategy & CCO06/30/202214,499
EASTHAM KARINDirector04/20/202249,350
O'Farrell Elizabeth G.Director08/21/202030,173
O'Farrell Elizabeth G.Director01/10/20202,948
O'Farrell Elizabeth G.Director01/10/20201,080
BEHRS MELISSA KELLYEVP, Chief Business Officer04/09/2019241,270
Spiegel Robert J.Director09/13/2018516,550
Spiegel Robert J.Director09/13/20181,198,750
ROSENFIELD STEPHENEVP, Genl Counsel & Secretary08/24/20182,572,745
ROSENFIELD STEPHENEVP, Genl Counsel & Secretary08/24/20186,143,748
Bloom Olivia KyusukEVP, Chief Financial Officer05/29/20159,139
BEHRS MELISSA KELLYEVP BD and Port&Alliance Mgmt05/29/20159,139
Hofstaetter ThomasDirector03/18/201587,850
Hofstaetter ThomasDirector03/18/2015287,000
Bloom Olivia KyusukEVP, Chief Financial Officer05/29/20147,096
BEHRS MELISSA KELLYEVP Portfolio & Alliance Mgmt05/29/201410,135
BRADBURY DANIELDirector05/09/2014249,858
Bloom Olivia KyusukEVP, Chief Financial Officer04/01/201415,837
BEHRS MELISSA KELLYEVP Portfolio & Alliance Mgmt04/01/201426,220
SCARLETT JOHN APresident and CEO04/01/201351,500
BEHRS MELISSA KELLYSVP Alliance and Prog Mgmt01/17/201346,569
Kelsey Stephen MichaelEVP, R&D Head, CMO05/30/201212,741
EARP DAVIDSVP, Corp Transactions05/30/201237,202
Bloom Olivia KyusukVP, Chief Acctg Officer05/30/201215,110
BEHRS MELISSA KELLYSVP Strategic Portfolio Mgmt05/30/201225,907
SCARLETT JOHN APresident and CEO01/24/2012129,000
SCARLETT JOHN APresident and CEO01/24/2012129,000
KILEY THOMASDirector11/22/2011100,269
KILEY THOMASDirector10/05/2011101,500
Spink Katharine E.SVP Alliance Mgmt & Operations06/14/201196,689
LEBKOWSKI JANESVP, Chief Scientific Officer06/14/2011108,121
Kelsey Stephen MichaelEVP, R&D Head, CMO06/14/201120,792
BEHRS MELISSA KELLYSVP Strategic Portfolio Mgmt06/14/2011108,121
GREENWOOD DAVIDPresident, Interim CEO, CFO06/14/2011145,541
EARP DAVIDChief Legal Counsel06/14/2011108,121
Bloom Olivia KyusukVP, Chief Acctg Officer06/14/201129,947
Bloom Olivia KyusukVP, Chief Acctg Officer05/24/20115,364
Spink Katharine E.SVP Prgm Mgmt, Cell Therapies05/24/20111,873
BEHRS MELISSA KELLYSVP Strategic Portfolio Mgmt05/24/201113,298
EARP DAVIDSVP Bus Dev, Chief Patnt Couns05/24/201113,298
LEBKOWSKI JANESVP, Chief Scientific Officer05/24/201113,298
GREENWOOD DAVIDPresident, Interim CEO, CFO05/24/201119,945
Kelsey Stephen MichaelEVP, CMO, Oncology05/05/201168,407
Load More Insider Transactions
FUNDS WITH A POSITION IN GERON CORP.
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
RA CAPITAL MANAGEMENT, L.P.46,202,4251.52%No changeOther
BLACKROCK INC.42,172,6790.00227%13.49%Other
VIVO CAPITAL, LLC24,143,6814.17%46.11%Other
GEODE CAPITAL MANAGEMENT, LLC10,943,6490.00242%9.3%Other
ORBIMED ADVISORS LLC485,0000.02%NewOther
ALPS ADVISORS INC358,7820.00595%-7.12%Other
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)35,6750.00139%NewOther
AQR CAPITAL MANAGEMENT LLC29,9920.00012%-61.17%Other
CHANGE IN SHARES OUTSTANDING FOR GERON CORP.
STOCK BUYBACKS FOR GERON CORP.
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
2.72%
1Q
12/31/2023
06/30/2023
8.76%
2Q
12/31/2023
03/31/2023
9.33%
3Q
12/31/2023
09/30/2022
46.89%
5Q
12/31/2023
06/30/2022
47.39%
6Q
12/31/2023
03/31/2022
79.25%
7Q
12/31/2023
12/31/2021
79.90%
8Q
12/31/2023
09/30/2021
80.96%
9Q
12/31/2023
06/30/2021
82.02%
10Q
12/31/2023
03/31/2021
83.92%
11Q
12/31/2023
12/31/2020
86.50%
12Q
12/31/2023
09/30/2020
86.71%
13Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
2.72%
1Q
06/30/2023
8.76%
2Q
03/31/2023
9.33%
3Q
09/30/2022
46.89%
5Q
06/30/2022
47.39%
6Q
03/31/2022
79.25%
7Q
12/31/2021
79.90%
8Q
09/30/2021
80.96%
9Q
06/30/2021
82.02%
10Q
03/31/2021
83.92%
11Q
12/31/2020
86.50%
12Q
09/30/2020
86.71%
13Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR GERON CORP.
LOADING...